Chronic oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed a diet high in sucrose and saturated fat

Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Leprdb mice

(2018) Peter C. Reifsnyder et al.   Annals of the New York Academy of Sciences

Adipocyte-specific DKO of Lkb1 and mTOR protects mice against HFD-induced obesity, but results in insulin resistance

(2018) Yan Xiong et al.   JOURNAL OF LIPID RESEARCH

Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1

(2018) Dianxin Liu et al.   Molecular Metabolism

mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function

(2017) Vivian A. Paschoal et al.   IMMUNOBIOLOGY

mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion

(2017) William J. Quinn et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice

(2017) Laura J. den Hartigh et al.   PLoS One

Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes

(2016) Peter C. Reifsnyder et al.   Aging-US

Rapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue

(2016) Cassie M. Tran et al.   DIABETES

Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice

(2016) Tizhong Shan et al.   DIABETOLOGIA

Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease

(2016) Ai-Ling Lin et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning

(2016) Dianxin Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapamycin-induced metabolic defects are reversible in both lean and obese mice

(2016) Yuhong Liu et al.   Aging-US

Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

(2015) Sebastian I. Arriola Apelo et al.   AGING CELL

Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet

(2014) Olga V. Leontieva et al.   AGING CELL

Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice

(2014) Hongfeng Jiang et al.   DIABETOLOGIA

Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice

(2014) Kassem Makki et al.   PLoS One

Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

(2013) Richard A. Miller et al.   AGING CELL

Rapamycin extends murine lifespan but has limited effects on aging

(2013) Frauke Neff et al.   JOURNAL OF CLINICAL INVESTIGATION

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice

(2012) Vladimir N. Anisimov et al.   CELL CYCLE

Liver-specific p70 S6 Kinase Depletion Protects against Hepatic Steatosis and Systemic Insulin Resistance

(2012) Eun Ju Bae et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity

(2011) Shi-Bing Yang et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Macrophages, Inflammation, and Insulin Resistance

(2010) Jerrold M. Olefsky et al.   Annual Review of Physiology

Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice

(2010) W. L. BAEDER et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

(2010) V. P. Houde et al.   DIABETES

Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice

(2010) Richard A. Miller et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

(2010) Shomit Sengupta et al.   MOLECULAR CELL

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

(2010) Patricia Spilman et al.   PLoS One

Long-term Administration of Rapamycin Reduces Adiposity, but Impairs Glucose Tolerance in High-Fat Diet-fed KK/HlJ Mice

(2009) Geng-Ruei Chang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice

(2009) Geng-Ruei Chang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

(2009) David E. Harrison et al.   NATURE

Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span

(2009) C. Selman et al.   SCIENCE

Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

(2008) B. L. Kasiske et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Dietary Cholesterol Worsens Adipose Tissue Macrophage Accumulation and Atherosclerosis in Obese LDL Receptor–Deficient Mice

(2008) Savitha Subramanian et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

(2008) Thomas Porstmann et al.   Cell Metabolism

Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration

(2008) Pazit Polak et al.   Cell Metabolism

mTOR Inhibition by Rapamycin Prevents  -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

(2008) M. Fraenkel et al.   DIABETES

Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients

(2008) O. Johnston et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors

(2007) Josep M. Cruzado   Transplantation Reviews